MDCO The Medicines Company

24.34
+0.44  (+2%)
Previous Close 23.9
Open 24.1
Price To Book -67.61
Market Cap 1797805364
Shares 73,862,176
Volume 342,235
Short Ratio
Av. Daily Volume 1,432,237

NewsSee all news

  1. The Medicines Company Announces Upcoming Investor Conference Presentations
  2. The Medicines Company to Announce Fourth-Quarter and Full-Year 2018 Financial Results on February 27
  3. Will Medicines Co. (MDCO) Report Negative Q4 Earnings? What You Should Know
  4. Is the Options Market Predicting a Spike in Medicines Company (MDCO) Stock?
  5. See what the IHS Markit Score report has to say about Medicines Co.

SEC filingsSee all SEC filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19606600
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19601064
  3. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19594940
  4. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19588376
  5. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19585116

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data 3Q 2019.
Inclisiran - ORION-9
Hypercholesterolemia
Development discontinued due to poor effiacy - November 7, 2016.
MDCO-216 - MILANO-PILOT
Acute coronary syndrome (ACS)
Approved August 29, 2017.
Meropenem-vaborbactam
Complicated urinary tract infections (cUTI)
CRL April 30 2014. Approved June 22 2015
Cangrelor
Reduction of thrombotic cardiovascular events including stent thrombosis in patients with coronary artery disease undergoing percutaneous coronary intervention (PCI)
Approved April 30, 2015.
IONSYS
Acute postoperative pain
Approved August 6 2014 under priority review.
Oritavancin
ABSSSI
Phase 3 trial to be initiated 1H 2018.
Inclisiran
Homozygous familial hypercholesterolemia (HoFH)
Phase 3 enrollment target met - noted March 9, 2018. Data due 3Q 2019.
Inclisiran - ORION-10
Cardiovascular disease (ASCVD)
Phase 3 target enrollment met - noted January 25, 2018. Data due 3Q 2019.
Inclisiran - ORION 11
Cardiovascular disease (ASCVD)

Latest News

  1. The Medicines Company Announces Upcoming Investor Conference Presentations
  2. The Medicines Company to Announce Fourth-Quarter and Full-Year 2018 Financial Results on February 27
  3. Will Medicines Co. (MDCO) Report Negative Q4 Earnings? What You Should Know
  4. Is the Options Market Predicting a Spike in Medicines Company (MDCO) Stock?
  5. See what the IHS Markit Score report has to say about Medicines Co.
  6. Alnylam's (ALNY) Q4 Earnings and Revenues Beat Estimates
  7. Factors of Influence in 2019, Key Indicators and Opportunity within Leidos, Nomad Foods, Huron Consulting Group, Casella Waste, The Medicines, and Aurinia Pharmaceuticals — New Research Emphasizes Economic Growth
  8. Need To Know: The Medicines Company (NASDAQ:MDCO) Insiders Have Been Buying Shares
  9. Top Picks 2019- The Medicines Company MDCO
  10. The Medicines Company Announces 5th Review of Un-blinded Data and Recommendation by Independent Data Monitoring Committee to Continue Inclisiran Phase 3 Trials
  11. Implied Volatility Surging for Medicines Company (MDCO) Stock Options
  12. Mallinckrodt's Inhaled Xenon Gas Therapy Enters Phase III
  13. Insider Buys Of The Week: Chesapeake Energy, Medicines Company, NuStar Energy

SEC Filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19606600
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19601064
  3. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19594940
  4. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19588376
  5. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19585116
  6. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19583182
  7. SC 13G - Statement of acquisition of beneficial ownership by individuals 19573423
  8. SC 13G - Statement of acquisition of beneficial ownership by individuals 19570857
  9. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19555680
  10. 8-K - Current report 19525165